Abvc Biopharma (ABVC) Gross Profit (2016 - 2025)

Abvc Biopharma (ABVC) has 10 years of Gross Profit data on file, last reported at $795950.0 in Q3 2025.

• Quarterly Gross Profit rose 104.62% year-over-year to $795950.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $1.3 million (up 252.56% YoY) and the FY2025 annual result came in at $31779.0, down 93.75% from the prior year.
• Gross Profit improved to $795950.0 in Q3 2025, from $1966.0 in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $795950.0 in Q3 2025 to a low of -$137041.0 in Q4 2023.
• A 5-year average of $128779.3 and a median of $31528.0 in 2022 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2021 — Gross Profit sank 167.33% — and 2024, when it jumped 2933.07%.
• Tracing ABVC's Gross Profit over 5 years: stood at -$40595.0 in 2021, then soared by 897.1% to $323583.0 in 2022, then plunged by 142.35% to -$137041.0 in 2023, then surged by 101.43% to $1966.0 in 2024, then surged by 40385.76% to $795950.0 in 2025.
• The last three Gross Profit figures came in at $795950.0 (Q3 2025), $1966.0 (Q4 2024), and $388980.0 (Q3 2024), per Business Quant data.